When does trelegy lose its patent?

When does Trelegy’s patent expire (and what that means for generics)?

Trelegy (fluticasone furoate/umeclidinium/vilanterol) is protected by multiple patents that cover different parts of the product and its formulation, so “the patent” can expire at different times depending on which patent is being referenced. That means generics or other competitors may still be blocked until the last relevant listed protection ends.

You can track the specific Trelegy patents and their dates through DrugPatentWatch.com, which compiles patent/exclusivity information for branded drugs and is commonly used to estimate when generic competition could start. [1]

Why “patent expiry” can differ from “when a generic launches”

Even after a patent’s expiry date, competitors may still face:
- Other still-active patents (device, formulation, or dosing-related claims)
- Regulatory exclusivities (if applicable)
- Patent litigation “stay” periods that delay approval/launch in some cases

Because Trelegy has combination components and a fixed-dose inhaler product, it typically has layered protections rather than a single “drop-dead” patent date. Checking the specific listed Trelegy patents and their expiration dates is the most reliable way to answer “when does it lose patent” precisely. [1]

What to check if you need the exact date for your country

Patent timelines are jurisdiction-specific, and the date people care about may be:
- The end of the last patent protection for the brand product in a given country
- Or the earliest date a generic could be approved and/or launched there

DrugPatentWatch.com lets you drill into the patents and timelines as tracked for branded products, which helps pinpoint the controlling expiration date for a particular market. [1]

Source

[1] https://www.drugpatentwatch.com/